Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis

Journal of the American Society of Nephrology

Volumn 7, Issue 11, 1996, Pages 2403-2408

  Coles, G A ^a  

^a Cardiff Royal Infirmary   (United Kingdom)

Author keywords

CAPD; Exit site infection; Mupirocin; Prevention; S. aureus

Indexed keywords

PSEUDOMONIC ACID;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CARRIER; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NOSE SMEAR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0030368545     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Buoncristiani V, Bianchi P, Cozzri M: A new safe simple connection system for CAPD. Int J Nephrol Urol Androl 1980;1:50-53.
2. Burkart JM, Hylander B, Durnell-Figel T, Roberts D: Comparison of peritonitis rates during long-term use of standard spike versus ultraset in continuous ambulatory peritoneal dialysis. Perit Dial Int 1990;10:41-43.
3. Holley JL, Bernardini J, Piraino B: Infecting organisms in continuous ambulatory peritoneal dialysis patients on the Y set. Am J Kidney Dis 1994;23:569-573.
4. Zimmerman SW O'Brien M, Wiedenhoeft FA, Johnson CA: Staphylococcus aureus peritoneal catheter-related infections: A cause of catheter loss and peritonitis. Perit Dial Int 1988;8:191-194.
5. Sewell CM Clarridge J, Lacke C, Weinman EJ, Young EJ: Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 1982;315:91-96.
6. Davies S J, Ogg CS, Cameron JS, Poston S, Noble WC: Staphylococcus aureus nasal carriage, exit site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989;9:61-64.
7. Sesso R, Draibe S, Castelo A, et al.: Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1989;31:264-268.
8. Yu VL, Goetz A, Wagener M, et al.: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-96.
9. Hudson IRB: The efficacy of intranasal mupirocin in the prevention of Staphylococcal infections: A review of recent experience. J Hosp Infect 1994;27:81-98.
10. Boelaert JR, De Smedt RA, De Baere YA, et al.: The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989;4:278-281.
11. Vonesh EF: Non-linear models for the analysis of longitudinal data. Stat Med 1992;11:1929-1954.
12. Luzar MA, Coles GA, Faller B, et al.: Staphylococcus aureus nasal carriage and infections in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990;332:505-509.
13. Piraino B, Bernadini J, Sorkin M: The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections and catheter loss in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1986;8:436-440.
14. Abraham G, Savin E, Ayiomamitis A, et al.: Natural history of exit-site infection (ESI) in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1988;8:211-216.
15. Prowant BF, Warady BA, Nolph KD: Peritoneal dialysis exit site care: Results of an international survey. Perit Dial Int 1993;13:149-154.
16. Ludlam HA, Young AE, Berry AJ, Philipps I: The prevention of infection with Staphylococcus aureus in continuous ambulatory peritoneal dialysis. J Hosp Infect 1989;14:293-303.
17. Luzar MA, Brown CB, Balf D, et al.: Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): Results of a randomized multicentre trial. Perit Dial Int 1990;10:25-29.
18. Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC: Vaccination for prevention of CAPD associated staphylococcal infection: Results of a prospective multicentre clinical trial. Clin Nephrol 1991;35:198-206.
19. Zimmerman SW, Ahreus E, Johnson CA, et al.: Randomised controlled trial of prophylactic rifampicin for peritoneal dialysis related infections. Am J Kidney Dis 1991;18:225-231.
20. Sesso R, Parisio K, Dalboni A, et al.: Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1994;41:370-376.
21. Reagan DR, Doebbeling BN, Pfaller MA, et al.: Elimination of coincidental Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-106.
22. Doebbeling BN, Reagon DR, Pfaller MA, Houston AK, Mollis RJ, Wenzel RP: Long-term efficacy of intranasal mupirocin ointment. Arch Intern Med 1994;154:1505-1508.
23. Holton DL, Nicolle LE, Diley D, Bernstein K: Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. J Hosp Infect 1991;17:133-137.
24. Boelaert JR, Van Landuyt HW, Godard CW, et al.: Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemia in haemodialysis patients. Nephrol Dial Transplant 1993;8:235-239.
25. Perez-Fontán M, Garcia-Falcón T, Rosales M, et al.: Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long-term results. Am J Kidney Dis 1993;22:708-712.
26. Piraino B, Bernardini J, Lutes R, Johnston J, Holley J: Randomised trial of mupirocin at exit site or oral rifampicin to prevent S. aureus infections [Abstract]. Perit Dial Int 1994;14[Suppl 1]:S27.
27. Weaver ME, Dunbeck DC: Mupirocin (Bactroban R) causes permanent structural changes in peritoneal dialysis (PD) catheters [Abstract]. Peril Dial Int 1994; 14[Suppl 1]:S20.